Waldow S M, Lobraico R V, Kohler I K, Wallk S, Fritts H T
Wenske Laser Center, Department of Surgery, Ravenswood Hospital Medical Center, Chicago.
Lasers Surg Med. 1987;7(6):451-6. doi: 10.1002/lsm.1900070602.
Photodynamic therapy, employing either hematoporphyrin derivative or dihematoporphyrin ether as the photosensitizer and an argon-pumped tunable dye laser as the activating light source, was used to treat ten patients who had primary or recurrent basal or squamous cell carcinoma or infiltrating ductal cell carcinoma lesions metastatic to the skin. Of the 155 sites that were treated, various degrees of edema, erythema, and necrosis, sometimes accompanied by blistering, were evident in all areas within 24 to 48 hours of light treatment. While our follow-up periods are short, four patients are free of disease at eight months or more posttreatment, two patients have had recurrent and/or persistent disease within four months, and four patients died within nine months from metastatic disease or unrelated disorders. Continued investigation into the use of photodynamic therapy for treatment of malignant lesions appears warranted, based on these preliminary clinical results.
采用血卟啉衍生物或双血卟啉醚作为光敏剂，并用氩离子泵浦可调谐染料激光器作为激活光源的光动力疗法，被用于治疗10例患有原发性或复发性基底细胞癌、鳞状细胞癌或已转移至皮肤的浸润性导管细胞癌病变的患者。在接受治疗的155个部位中，在光治疗后的24至48小时内，所有区域均出现了不同程度的水肿、红斑和坏死，有时还伴有水疱形成。虽然我们的随访期较短，但4例患者在治疗后8个月或更长时间内无疾病复发，2例患者在4个月内出现疾病复发和/或持续存在，4例患者在9个月内死于转移性疾病或无关疾病。基于这些初步临床结果，继续研究光动力疗法在治疗恶性病变中的应用似乎是有必要的。
